Who is eligible for clinical trial NCT06261021?

Participants must meet protocol criteria for Discoid Lupus Erythematosus. Confirm exact inclusion and exclusion requirements with the study coordinator.

Does clinical trial NCT06261021 provide travel or cost reimbursement?

Check with the site coordinator at the participating facility for travel and lodging stipend availability, and for which routine-care costs are covered.

🏛️ Verified NIH Record • Updated 2025-03-21

Study to Evaluate the Efficacy of Ruxolitinib 1.5% Cream in Adult Subjects with Discoid Lupus Erythematosus (NCT06261021)

🟢 Recruiting Phase2 💊 Investigational Drug / Biologic Sponsor: Innovaderm Research Inc.

🩺 Plain-English Summary (8th-Grade Level)

This study is a single-blind, intraindividual study to evaluate the efficacy of ruxolitinib 1.5 % cream in adult subjects with discoid lupus erythematosus.

Who can join: To join this study, participants generally need to meet the listed inclusion criteria (7 items) and avoid the listed exclusions (15 items).

Location: INNO-6051 Site 03 — Fredericton, New Brunswick

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

Male or female subject 18 years of age or older at the time of consent.
Confirmed DLE diagnosis.
Subject has moderate to severe DLE, as defined by an overall CLA IGA score of 3 (moderate) or 4 (severe) at screening and Day 1.
Female subject of childbearing potential must have a negative urine pregnancy test at screening and negative urine pregnancy test at Day 1.
Subject has no known history of latent or active tuberculosis (TB) infection.
Subject is willing to participate and is capable of giving informed consent. Note: Consent must be obtained prior to any study-related procedures.
Subjects must be willing to comply with all study procedures and must be available for the duration of the study.

Usually NOT eligible if any of the following apply:

Exclusion Criteria:
Female subject who is breastfeeding, pregnant, or who is planning to become pregnant during the study.
Subject has a history of skin disease or presence of skin condition that would interfere with the study assessments.
Subject has unstable or fluctuating use of nicotine-containing products within 4 weeks prior to screening.
Subject is known to have immune deficiency or is immunocompromised.
Subject is ≥ 50 years old AND has a history of heart attack, other clinically significant heart problems, stroke, or blood clots.
Subject has a known history of chronic infectious disease (e.g., hepatitis B, hepatitis C, or human immunodeficiency virus \[HIV\]).
Subject is known to have hepatitis B or hepatitis C viral infection.
Subject has used any topical medicated treatment that could affect DLE within 2 weeks prior to Day 1, including, but not limited to, topical corticosteroids, retinoids, calcineurin inhibitors, antimicrobials, and medical devices.
Subject has received any marketed or investigational biological agent within 12 weeks or 5 half lives (whichever is longer) prior to Day 1, including but not limited to ustekinumab and rituximab.
Subject is currently receiving a nonbiological investigational product or device or has received one within 4 weeks prior to Day 1.
Subject has a known or suspected allergy to ruxolitinib.

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (2 Sites)

INNO-6051 Site 03 — Fredericton, New Brunswick
Innovaderm Research Inc. — Montreal, Quebec

💰 Cost, Insurance & Patient Rights

100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

🏛️ View Official NIH Record ↗